[1]
|
Kohler, B.A., Sherman, R.L., Howlader, N., Jemal, A., Ryerson, A.B., Henry, K.A., Boscoe, F.P., Cronin, K.A., Lake, A., Noone, A.-M., Henley, S.J., Eherman, C.R., Anderson, R.N. and Penberthy, L. (2015) Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State. Journal of the National Cancer Institute, Online 30 March 2015.
|
[2]
|
Williams, C. and Lin, C.-Y. (2013) Oestrogen Receptors in Breast Cancer: Basic Mechanisms and Clinical Implications. Ecancermedicalscience, 7, 370-382.
|
[3]
|
Munster, P.N., Thurn, K.T., Thomas, S., Raha, P., Lacevic, M., Miller, A., Melisko, M., Ismail-Khan, R., Rugo, H., Moasser, M. and Minton, S.E. (2011) A Phase II Study of the Histone Deacetylase Inhibitor Vorinstat Combined with Tamoxifen for the Treatment of Patients with Hormone Therapy-Resistant Breast Cancer. British Journal of Cancer, 104, 1828-1835. http://dx.doi.org/10.1038/bjc.2011.156
|
[4]
|
Shen, C., Huang, Y., Liu, Y., Wang, G., Zhao, Y., Wang, Z., Ten, M., Wang, Y., Flockhart, D.A., Skaar, T.C., Yan, P., Nephew, K.P., Huang, T.H.M. and Li, L. (2011) A Modulated Empirical Bayes Model for Identifying Topological and Temporal Estrogen Receptor Alpha Regulatory Networks in Breast Cancer. BMC Systems Biology, 5, 67-83. http://dx.doi.org/10.1186/1752-0509-5-67
|
[5]
|
Kubo, M., Kanaya, N., Petrossian, K., Ye, J., Warden, C., Liu, Z., Nishimura, R., Osako, T., Okido, M., Shimada, K., Takahashi, M., Chu, P., Yuan, Y.-C. and Chen, S. (2013) Inhibition of the Proliferation of Acquired Aromatase Inhibitor-Resistant Breast Cancer Cells by Histone Deacetylase Inhibitor LBH589 (Panobinostat). Breast Cancer Research and Treatment, 137, 93-107. http://dx.doi.org/10.1007/s10549-012-2332-x
|
[6]
|
Del Pup, L. (2012) Management of Vaginal Dryness and Dyspareunia in Estrogen Sensitive Cancer Patients. Gynecological Endocrinology, 28, 740-745. http://dx.doi.org/10.3109/09513590.2011.652717
|
[7]
|
Santos, I. and Clissold, S. (2010) Urogenital Disorders Associated with Estrogen Deficiency: The Role of Promestriene as Topical Oestrogen Therapy. Gynecological Endocrinology, 26, 644-651. http://dx.doi.org/10.3109/09513591003767948
|
[8]
|
Wolff, J.-P., Cachelou, R. and Gueritee, N. (1982) Absence of Systemic Hormonal Effects in an Oestradiol Diether Topically Active on the Vaginal Mucosa. Maturitas, 4, 239-246. http://dx.doi.org/10.1016/0378-5122(82)90054-8
|
[9]
|
Howell, A., Clarke, R.B., Evans, G., Bundred, N., Cuzick, J., Santen, R. and Allred, C. (2007) Estrogen Deprivation for Breast Cancer Prevention. Recent Results in Cancer Research, 174, 151-167. http://dx.doi.org/10.1007/978-3-540-37696-5_13
|
[10]
|
Wills, S., Ravipati, A., Venuturumilli, P., Kesge, C., Folkerd, E., Dowsett, M., Hayes, D.F. and Decker, D.A. (2012) Effects of Vaginal Estrogens on Serum Estradiol Levels in Postmenopausal Breast Cancer Survivors and Women at Risk of Breast Cancer Taking an Aromatase Inhibitor or a Selective Estrogen Receptor Modulator. Journal of Oncology Practice, 11, 144-148. http://dx.doi.org/10.1200/JOP.2011.000352
|
[11]
|
Fiers, T., Casetta, B., Bernaert, B., Vandersypt, E., Debock, M. and Kaufman, J.M. (2012) Development of a Highly Sensitive Method for the Quantification of Estrone and Estradiol in Serum by Liquid Chromatography Tandem Mass Spectrometry without Derivatization. Journal of Chromatography B, 893-894, 57-62. http://dx.doi.org/10.1016/j.jchromb.2012.02.034
|
[12]
|
Rae, J.M., Johnson, M.D., Scheys, J.O., Cordero, K.E., Larios, J.M. and Lippman, M.E. (2005) GREB1 Is a Critical Regulator of Hormone Dependent Breast Cancer Growth. Breast Cancer Research and Treatment, 92, 141-149. http://dx.doi.org/10.1007/s10549-005-1483-4
|
[13]
|
Mohammed, H., D’Santos, C., Serandour, A.A., Ali, H.R., Brown, G.D., Atkins, A., Rueda, O.M., Holmes, K.A., Theodorou, V., Robinson, J.L.L., Zwart, W., Saadi, A., Ross-Innes, C.S., Chin, S.-F., Menon, S., Stingl, J., Palmieri, C., Caldas, C. and Carroll, J.S. (2013) Endogenous Purification Reveals GREB1 as a Key Estrogen Receptor Regulatory Factor. Cell Reports, 3, 342-349. http://dx.doi.org/10.1016/j.celrep.2013.01.010
|
[14]
|
Ghosh, M.G., Thompson, D.A. and Weigel, R.J. (2000) PDZK1 and GREB1 Are Estrogen-Regulated Genes Expressed in Hormone-Responsive Breast Cancer. Cancer Research, 60, 6367-6375.
|
[15]
|
Dunbier, A.K., Anderson, H., Ghazoui, Z., Folkerd, E.J., A’hern, R., Crowder, R.J., Hoog, J., Smith, I.E., Osin, P., Nerurkar, A., Parker, J.S., Perou, C.M., Ellis, M.J. and Dowsett, M. (2010) Relationship between Plasma Estradiol Levels and Estrogen-Responsive Gene Expression in Estrogen Receptor-Positive Breast Cancer in Postmenopausal Women. Journal of Clinical Oncology, 28, 1161-1167. http://dx.doi.org/10.1200/JCO.2009.23.9616
|
[16]
|
Zwart, W., Theodorou, V., Kok, M., Canisius, S., Linn, S. and Carroll, J.S. (2011) Oestrogen Receptor-Co-Factor-Chromatin Specificity in the Transcriptional Regulation of Breast Cancer. The EMBO Journal, 30, 4764-4776. http://dx.doi.org/10.1038/emboj.2011.368
|
[17]
|
Liu, M., Wang, G., Gomez-Fernandez, C.R. and Guo, S. (2012) GREB1 Functions as a Growth Promoter and Is Modulated by IL6/STAT3 in Breast Cancer. PLoS ONE, 7, e46410. http://dx.doi.org/10.1371/journal.pone.0046410
|
[18]
|
Englert, N.A., Spink, B.C. and Spink, D.C. (2011) Persistent and Non-Persistent Changes in Gene Expression Result from Long-Term Estrogen Exposure of MCF-7 Breast Cancer Cells. The Journal of Steroid Biochemistry and Molecular Biology, 123, 140-150. http://dx.doi.org/10.1016/j.jsbmb.2010.12.010
|
[19]
|
Meng, Q., Chen, X., Sun, L., Zhao, C., Sui, G. and Cai, L. (2011) Carbamazepine Promotes Her-2 Protein Degradation in Breast Cancer Cells by Modulating HDAC6 Activity and Acetylation. Molecular and Cellular Biochemistry, 348, 165-171. http://dx.doi.org/10.1007/s11010-010-0651-y
|
[20]
|
Yardley, D.A., Ismail-Khan, R.R., Melichar, B., Lichinitser, M., Munster, P.N., Klein, P.M., Cruickshank, S., Miller, K.D., Lee, M.J. and Trepel, J.B. (2013) Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane with or without Entinostat in Postmenopausal Women with Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment with a Nonsteroidal Aromatase Inhibitor. Journal of Clinical Oncology, 31, 2128-2135. http://dx.doi.org/10.1200/JCO.2012.43.7251
|